According to Dr. Michael Weber, many patients will often present at the physician’s office with previously undiagnosed or unrecognized risk factors, which occurs frequently with high blood pressure, lipid disorders, and diabetes. Consequently, initial therapeutic strategies must be aggressive to properly control those who are truly at high risk. However, according to the panelists, not all patients are the same, not all patients are diagnosed at the same time, and there are countless variables that may impact the trajectory of a disease state. Therefore, it is vital to emphasize and drive personalized medicine with individualized goals. While there are contentions among different patient populations regarding the merits of pharmacotherapy and lifestyle modifications, the panelists believe that a comprehensive and balanced strategy is what will garner the most beneficial outcomes.
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen
From Red Tape to Relief: Rewriting the Rules of Prior Authorization
June 23rd 2025Up to 257 million Americans could benefit from these prior authorization reforms that could have cross-market implications on health care plans administered through commercial insurers, Medicare Advantage, and Medicaid.
Read More
Moving Evidence From Research to Practice: Q&A With Ken Cohen, MD
June 23rd 2025In 2025, each issue of Population Health, Equity & Outcomes will feature a profile of a health system leader transforming care in their area of expertise. This issue spotlights a conversation with Ken Cohen, MD, executive director of translational research at Optum Health.
Read More